Latest News Releases

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 04, 2024

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta046/03.06.2024/19:55) - The capital increase from authorized capital resolved by the Management Board and Supervisory Board of Biofrontera AG on April 04, 2024 has been fully placed. According to the preliminary result of the subscription offer, the capital increase is oversubscribed after the exercise of subscription rights and oversubscription rights. 3,038,431 new shares will be issued at a subscription price of EUR 1.10 per share.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate

[ source: https://www.pressetext.com/news/20240603046 ]

Biofrontera AG – an attractive investment

We are experts in photodynamic therapy. With our innovative products and treatment methods, we make our contribution to skin health and at the same time create value for our investors.

Biofrontera is listed on the Frankfurt Stock Exchange (B8FK).